• 1
    Prioritization CoCER. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: Then National Academies Press, 2009
  • 2
    Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 68795
  • 3
    Appell RA, Sand P, Dmochowski R et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 35863
  • 4
    Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 46470
  • 5
    Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 23742
  • 6
    Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003; 92: 7417
  • 7
    Yamaguchi O, Marui E, Kakizaki H et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 2007; 100: 57987
  • 8
    Junemann KP, Halaska M, Rittstein T et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 2005; 48: 47882
  • 9
    Herschorn S, Swift S, Guan Z et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010; 105: 5866
  • 10
    ICH Expert Working Group. Statistical principles for clinical trials E9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1998
  • 11
    Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 178796
  • 12
    Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998; 63: 52939
  • 13
    Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46: 55663
  • 14
    Detrol® LA (tolterodine tartrate). Full Prescribing Information. New York: Pfizer Inc, 2008
  • 15
    Toviaz® (fesoterodine fumarate). Full Prescribing Information. New York: Pfizer Inc, 2008
  • 16
    European Medicines Agency (EMEA). EPARs for authorized medicinal products for human use. European Public Assessment Report for Toviaz (Product Information). Updated August 2009. Available at: Accessed 20 October 2009
  • 17
    Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 120412
  • 18
    Chapple C, Van Kerrebroeck P, Juenemann K, Wang J, Brodsky M. Comparison of fesoterodine and tolterodine in subjects with overactive bladder. BJU Int 2008; 102: 112832
  • 19
    Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006; 68: 916
  • 20
    Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 107986
  • 21
    Cardozo L, Coyne KS, Versi E. Validation of the Urgency Perception Scale. BJU Int 2005; 95: 5916
  • 22
    Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 56374
  • 23
    Box GEP, Hunter WG, Hunter JS. Statistics for Experimenters. New York: Wiley, 1978
  • 24
    Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1960; 37: 35161
  • 25
    Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 138895
  • 26
    Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008; 24: 351321
  • 27
    Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002; 24: 61628
  • 28
    Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 23115
  • 29
    Cardozo L, Hessdorfer E, Milani R et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102: 11207